Online inquiry

IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8883MR)

This product GTTS-WQ8883MR is a type of mRNA modified with 5-Methyl-CTP, which ecodes the monoclonal antibody that targets IFNA1; IFNB1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_024013.3; NM_002176.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3439; 3456
UniProt ID P01562; P01574
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ8883MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9300MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMP-321
GTTS-WQ10375MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY2062430
GTTS-WQ13204MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ15506MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA UCB-7665
GTTS-WQ1923MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AGN 150998
GTTS-WQ1775MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ15388MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA TRU-016
GTTS-WQ5435MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDA 1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW